Pharming Group N.V. stock is down -4.81% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 22 December’s closed higher than November.
Pharming Group N.V. develops and commercialize protein replacement therapies and precision medicines. Ruconest, a recombinant human C1 esterase inhibitor, is used for the treatment of acute hereditary angioedema. RhC1INH, leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K Delta syndrome; and alpha-glucosidase therapy for the. treatment of pompe and fabry diseases.